会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Method and device for decreasing contamination
    • US20080038207A1
    • 2008-02-14
    • US11827031
    • 2007-07-10
    • David EdwardsMark GabrielsonRobert ClarkeWesley DehaanMatthew BrandeJonathan Man
    • David EdwardsMark GabrielsonRobert ClarkeWesley DehaanMatthew BrandeJonathan Man
    • A61K31/70A01N37/18
    • A61B5/097G01N33/497
    • Methods and devices to determine rate of particle production and the size range for the particles produced for an individual are described herein. The device (10) contains a mouthpiece (12), a filter (14), a low resistance one-way valve (16), a particle counter (20) and a computer (30). Optionally, the device also contains a gas flow meter (22). The data obtained using the device can be used to determine if a formulation for reducing particle exhalation should be administered to an individual. This device is particularly useful prior to and/or following entry in a cleanroom to ensure that the cleanroom standards are maintained. The device can also be used to identify animals and humans who have an enhanced propensity to exhale aerosols (referred to herein as “over producers”, “super-producers”, or “superspreaders”). Formulations to reduce particle production are also described herein. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body. When applied to mucosal lining fluids, the formulation alters the physical properties such as the gel characteristics at the air/liquid interface, surface elasticity, surface viscosity, surface tension and bulk viscoelasticity of the mucosal lining. The formulation is administered in an effective amount to minimize ambient contamination due to particle formation during breathing, coughing, sneezing, or talking, which is particularly important in cleanroom applications. In one embodiment, the formulation for administration is a non-surfactant solution. In one embodiment, the formulations are conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment. Preferably the formulation is administered in the form of an aerosol.
    • 3. 发明申请
    • Formulations decreasing particle exhalation
    • 减少颗粒呼气的配方
    • US20070270502A1
    • 2007-11-22
    • US11714999
    • 2007-03-06
    • David EdwardsJonathan ManJeffrey KatstraRobert Clarke
    • David EdwardsJonathan ManJeffrey KatstraRobert Clarke
    • A61K47/00
    • A61K47/02A61K9/0078A61K9/14A61K9/141A61K9/16A61M15/00
    • Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
    • 已经开发了用于肺部输送以治疗或降低人类感染病毒感染,特别是结核病,SARS,流感和呼吸道合成病毒以及动物蹄和口蹄疫等疾病或减轻过敏或其他肺部疾病症状的传染性的制剂 疾病。 用于肺部给药的制剂包括显着改变诸如等渗盐水和任选的载体的肺粘液衬里液体的表面张力和表面弹性的物理性质的材料。 制剂可以作为液体溶液,悬浮液,气雾剂或粉末施用,其中颗粒基本上由渗透活性的溶质组成。 药物,特别是抗病毒剂或抗生素,可以任选地包括在制剂中。 这些可以与制剂一起施用或掺入制剂中。